8-K

\                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                 -------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE

                        SECURITIES EXCHANGE ACT OF 1934

        Date of Report (Date of earliest event reported)  June 30, 2003
                        --------------------------------



                           INTEGRATED BIOPHARMA, INC.
- --------------------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

         Delaware                     000-28876               22-2407475
- --------------------------------------------------------------------------------
(State or Other Jurisdiction       (Commission              (IRS Employer
    of Incorporation)              File Number)          Identification No.)

201 Route 22, Hillside, New Jersey                              07205
- --------------------------------------------------------------------------------

           (Address of Principal Executive Offices)          (Zip Code)

   Registrant's telephone number, including area code         (973) 926-0816
                  --------------------------------------------

                                 NOT APPLICABLE
- --------------------------------------------------------------------------------
         (Former Name or Former Address, if Changed Since Last Report)



Item 5.  Other Events and Required FD Disclosure.

     On June 30, 2003, Integrated BioPharma, Inc., a Delaware corporation,
issued a press release regarding completion of a private placement.  The press
release is included as Exhibit 99.1 to this Form 8-K and is incorporated herein
by reference.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

Exhibit No.     Description
- -----------     -----------
99.1            Press Release, dated June 30, 2003, entitled "Integrated
                BioPharma Completes $9.5 Million Private Placement."

                                   SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                     INTEGRATED BIOPHARMA, INC.
Date:   July 10, 2003



                                     By: /s/ Eric Friedman
                                     ----------------------
                                     Name:   Eric Friedman
                                     Title:  Chief Financial Officer

EX-99.1

[INTEGRATED BIOPHARMA LOGO]
                                                                    Exhibit 99.1

FOR IMMEDIATE RELEASE                Contact:  Lance Baller
- ---------------------                Vice President of Corporate
June 30, 2003                        Development & Communications
                                     Integrated BioPharma, Inc.
                                     (303) 470-0055

         INTEGRATED BIOPHARMA COMPLETES $9.5 MILLION PRIVATE PLACEMENT

Hillside, NJ. June 30, 2003 -- Integrated BioPharma, Inc. (Amex: INB), a leading
biopharmaceutical company, today announced that it has raised $9.5 million in
net proceeds from the sale of approximately 9,500 shares of newly issued INB
Series A Convertible Preferred Stock in a private placement at a price of $1000
per share.  The Series A Convertible Preferred Stock,  initially convertible at
$8 thru June 30, 2004, at $12 thru June 30, 2005 and at $16 thru June 30, 2006
into shares of the Company's Common Stock.  The holders of the Series A
Preferred on each anniversary of the initial closing shall be entitled to
receive cumulative dividends and in preference to any dividend on the Common
Stock, at the rate of 4% of the Original Purchase Price per annum, Dividend
shall be payable in cash or in kind at the option of the Company.  The dividend
shall only be payable for fiscal years ending June 30, 2004, 2005 and 2006.   In
addition, the company issued warrants to purchase an additional 175,000 shares
of common stock at an exercise price of $5.40 per share to the investors. The
company retained no placement agents for this financing.

The Company expects to use the proceeds from the offering for general corporate
purposes, including working capital and potential acquisitions of products or
companies and licensing arrangements.

"This equity financing places Integrated BioPharma in an even stronger position
to pursue growth opportunities afforded by the company's strong product
development and distribution channels," said E. Gerald Kay, the company's chief
executive officer.

The Series A Convertible Preferred Stock and the Common Stock issuable upon
conversion of the Series A Convertible Preferred Stock have not been registered
under the Securities Act of 1933, as amended, or any state securities laws, and
unless so registered, may not be offered or sold in the United States, except
pursuant to an applicable exemption from the registration requirements of the
Securities Act of 1933, as amended, and any state securities laws. This press
release does not constitute an offer to sell or the solicitation of an offer to
buy securities.

                                                                    Exhibit 99.1


About Integrated BioPharma

Integrated BioPharma, Inc. is a well-established biopharma company serving the
varied needs of the nutraceutical, biotechnology and pharmaceutical industries.
Through a number of wholly owned subsidiaries INB develops, manufactures and
distributes, worldwide over 130 products. The Company has recently upgraded and
expanded its manufacturing facilities to further increase production capacity.
A leader for many years in providing nutritional supplement products and
services, the Company's recent acquisitions propel it into the rapidly growing
field of genetically engineered human therapeutics. These acquired companies
already have significant competitive presence in the high growth industry of
development and commercialization of naturally occurring chemotherapeutic
anti-cancer agents.  Our lead natural product pharmaceutical will be API
paclitaxel, a chemotherapeutic drug used in the treatment of breast, ovarian and
other cancers.  Integrated BioPharma's solid business base, long standing
industry reputation and experienced management team ensure rapid and significant
growth in the coming years. Integrated BioPharma currently consists of eight
operating units with significant competitive advantages derived from shared
resources, synergies and economies of scale.  Further information is available
at www.iBioPharma.com.
   ------------------

     Statements included in this release may constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of
1995. Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and the company's
ability to obtain new contracts and accurately estimate net revenues due to
variability in size, scope and duration of projects, and internal issues in the
sponsoring client. Further information on potential factors that could affect
the company's financial results can be found in the company's Reports filed with
the Securities and Exchange Commission.